Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27764382 | 1.00 | OPRL1 (0.41) | OPRL1OPRM1OPRD1OPRK1DPP4 | |
| SCHEMBL28280956 | 0.87 | OPRM1 (0.51) | OPRL1OPRM1OPRD1OPRK1DPP4 | |
| SCHEMBL28280954 | 0.87 | OPRM1 (0.51) | OPRL1OPRM1OPRD1OPRK1DPP4 | |
| SCHEMBL28282701 | 0.87 | OPRM1 (0.51) | OPRL1OPRM1OPRD1OPRK1DPP4 | |
| SCHEMBL28280983 | 0.78 | OPRM1 (0.48) | OPRL1OPRM1OPRD1OPRK1DPP4 | |
| SCHEMBL28870396 | 0.78 | OPRM1 (0.48) | OPRL1OPRM1OPRD1OPRK1DPP4 | |
| SCHEMBL28280982 | 0.78 | OPRM1 (0.48) | OPRL1OPRM1OPRD1OPRK1DPP4 | |
| SCHEMBL27764383 | 0.78 | OPRM1 (0.37) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4884481 | 0.77 | ALDH1A1 (0.38) | OPRL1 | |
| SCHEMBL5347104 | 0.76 | KDM4E (0.54) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2099454-A2 | AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS | Abbott Laboratories (US) | 2009-09-16 | — | — | EP | disclosed |
| CN-101534824-A | Aminopyrrolidines as chemokine receptor antagonists | ABBOTT LAB (US) | 2009-09-16 | — | — | CN | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008060621-A2 | AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | OPRL1 98/4885OPRM1 189/4885OPRD1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.